Ashish Shrestha

Dr Ashish Shrestha

THRF Early Career Fellow

Adelaide Medical School

Faculty of Health and Medical Sciences


My research aim is to develop a universal hepatitis C virus (HCV) vaccine against the most common HCV genotypes found globally. This builds on the patented vaccine already developed by the Gowans group, and aims to generate a cocktail of four cytolytic DNA vaccines each of which evokes a broad immune response to a different genotype of HCV. I am also examining the ability of the existing cytolytic DNA vaccine to provide effective protection against the Zika virus (ZIKV). Zika and HCV belong to the same family of Flavivridae viruses and have a similar genome organisation, providing hope that generation of an analogous vaccine to the existing cytolytic DNA HCV vaccine is possible. Zika is an emerging disease, contracted after being bitten by an infected mosquito, which results in a non-specific illness with fever, rash, muscle and joint pain. Infected individuals can transmit the virus via infected blood or by sexual transmission. The major beneficiaries of a vaccine will be women of child-bearing age, as mothers infected during pregnancy are more likely to have children with microencephaly (small brain syndrome) for which there is no treatment.

My research aim is to develop a universal hepatitis C virus (HCV) vaccine against the  most common HCV genotypes found globally. This builds on the patented vaccine already developed by the Gowans group, and aims to generate a cocktail of four cytolytic DNA vaccines each of which evokes a broad immune response to a different genotype of HCV. I am also examining the ability of the existing cytolytic DNA vaccine to provide effective protection against the Zika virus (ZIKV). Zika and HCV belong to the same family of Flavivridae viruses and have a similar genome organisation, providing hope that generation of an analogous vaccine to the existing cytolytic DNA HCV vaccine is possible. Zika is an emerging disease, contracted after being bitten by an infected mosquito, which results in a non-specific illness with fever, rash, muscle and joint pain. Infected individuals can transmit the virus via infected blood or by sexual transmission. The major beneficiaries of a vaccine will be women of child-bearing age, as mothers infected during pregnancy are more likely to have children with microencephaly (small brain syndrome) for which there is no treatment.

    Expand
  • Appointments

    Date Position Institution name
    2012 - 2013 Lecturer Nepal Medical College
    2011 - 2012 Lecturer Gandaki Medical College Teaching Hospital and Research Centre
    2009 - 2010 QC Executive Genetica Laboratory
  • Education

    Date Institution name Country Title
    2013 - 2016 School of Medicine, The University of Queenland Australia PhD
    2005 - 2007 Tribhuvan University, Kathmandu Nepal MSc
    2002 - 2005 Tribhuvan University, Kathmandu Nepal BSc
  • Position: THRF Early Career Fellow
  • Phone: 82226590
  • Email: ashish.shrestha@adelaide.edu.au
  • Campus: North Terrace
  • Building: TQEH - Basil Hetzel Institute, floor 1
  • Org Unit: Adelaide Medical School

Connect With Me
External Profiles

Other Links